JPRN-UMIN000006257招募中未知
Pharmacokinetics and clinical outcomes of bortezomib in patients with newly diagnosed myeloma - Pharmacokinetics and clinical outcomes of bortezomib in patients with myeloma
Division of Hematology, Department of Medicine, Keio University, School of Meidicine0 个研究点目标入组 40 人开始时间: 2011年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients without consent 2) Patients with PS 3 or worse 3) ANC < 1,000/cmm 4) AST > or = 3 x upper limit, ALT > or = 3 x upper limit, TB > or = 2 x upper limit 5) Interstitial pneumonia diagnosed by imaging, pulmonary function test, or blood examination. Patients with increased level of KL-6 without any other findings suspicious of interstitial pneumonia are included. 6) Peripheral neuropathy grade 3 or higher 7) Drug allergy against bortezomib or dexamethasone 8) Primary physician thinks it is inappropriate to enroll the patient
研究者
相似试验
进行中（未招募）
1 期
EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMultiple myelomaEUCTR2019-002626-67-ESInstitut Català d'Oncologia360
已完成
不适用
To investigate the efficacy and safety of bortezomib as maintenance therapy for untreated multiple myeloma patients ineligible for autologous stem cell transplantatioMultiple myelomaJPRN-UMIN000007880Kanshinetsu Multiple Myeloma Group35
已完成
不适用
To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation.Multiple myelomaJPRN-UMIN000007838Kanshinetsu Multiple Myeloma Group47
进行中（未招募）
不适用
Phase II study of Proteasome inhibitor Bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma unspecified PTCLU and cutaneous T-cell lymphoma CTCL - NDRELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED PTCLU AND CUTANEOUS T-CELL LYMPHOMA CTCLMedDRA version: 6.1Level: PTClassification code 10034626EUCTR2005-005002-24-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI30
进行中（未招募）
1 期
A Phase 2 Relapsed or Refractory Multiple Myeloma trial - with orwithout Elotuzumab.Relapsed or Refractory Multiple MyelomaMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002695-16-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO150